A clinical-stage biopharmaceutical company developing novel therapies for serious diseases with significant R&D investment and a substantial cash balance to fund operations.
SLDB possesses a robust balance sheet with $80.2 million in cash and equivalents that can fund operations for several years, reducing immediate dilution risk for shareholders. The company's heavy investment in R&D ($96.4M) suggests high potential value if any clinical programs achieve approval, offering asymmetric upside for early investors. Management has successfully maintained a growing cash balance despite substantial operating losses, demonstrating effective capital allocation during the development phase.
The company is hemorrhaging cash with an annual burn rate exceeding $100 million and a net loss deepening to $-124.7 million, raising concerns about liquidity sustainability. With zero revenue and a massive retained earnings deficit of $-783.5 million, the business lacks any current profitability or product sales to support operations. Investors face significant downside risk if clinical trials fail or if financing markets tighten, potentially forcing distressed equity issuances.
Solid Biosciences Inc. (SLDB) is a biopharmaceutical company focused on developing novel therapies for serious diseases, primarily operating within the pharmaceutical research and development sector. The company leverages its extensive pipeline of clinical-stage assets to target unmet medical needs across oncology and other therapeutic areas. With no current revenue, the business model relies entirely on successful drug development and future commercialization or strategic partnerships to generate cash flow.
Management has deployed $96.4 million in research and development alongside share-based compensation of $10.5 million to advance its clinical pipeline, resulting in a net loss of $124.7 million for the latest period. Despite significant interest income of $9.5 million, operating cash flow remains negative at $100 million, necessitating continued reliance on financing activities which provided $122.4 million in inflows. The company's cash position grew to $82.2 million, but the trajectory of losses indicates a critical need for milestone achievements or capital raises.
The biopharmaceutical industry is characterized by high-risk, high-reward dynamics where companies invest billions in R&D to develop novel therapies for serious diseases like cancer. Success depends heavily on the ability to navigate complex regulatory pathways and secure funding during long clinical development phases before any commercial revenue is realized. Market leaders often possess significant cash reserves and diversified pipelines to withstand the financial volatility inherent in drug discovery.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $8.1M | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $8.1M | $0 | $0 |
| Operating Expenses | $114.5M | $104.3M | $129.7M |
| Operating Income | $-106.5M | $-104.3M | $-129.7M |
| R&D | $78.4M | $76.6M | $96.4M |
| G&A | $28.9M | $27.8M | $33.3M |
| Stock-Based Comp | $7.5M | $7.6M | $10.5M |
| D&A | $2.4M | $2.6M | $2.5M |
| Depreciation | $2.4M | $2.6M | — |
| Other OpEx | $7.2M | $-63.0K | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Income | $2.6M | $7.1M | $9.5M |
| Pre-Tax Income | $-106.5M | $-104.3M | $-129.7M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-106.5M | $-104.3M | $-129.7M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-86.0M | $-96.0M | $-124.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-86.0M | $-96.0M | $-124.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $219.6M | $129.7M | $157.3M |
| Cash & Equivalents | $155.4M | $74.0M | $80.2M |
| Prepaid Expenses | $5.9M | $6.1M | $8.4M |
| Other Current Assets | $58.3M | $49.6M | $68.7M |
| Long-Term Assets | $40.6M | $35.2M | $31.4M |
| PP&E (Net) | $9.7M | $6.6M | $4.7M |
| Operating Leases | $28.9M | $26.5M | $24.3M |
| Other LT Assets | $2.0M | $2.0M | $2.3M |
| Total Assets | $260.3M | $164.9M | $188.7M |
| Current Liabilities | $22.5M | $14.5M | $30.3M |
| Accounts Payable | $3.2M | $2.0M | $4.2M |
| Current Leases | $1.9M | $1.9M | $1.8M |
| Other Current Liab | $682.0K | $493.0K | $4.4M |
| Long-Term Liabilities | $26.1M | $23.9M | $21.2M |
| LT Operating Leases | $24.3M | $22.7M | $21.2M |
| Other LT Liab | $1.8M | $1.2M | $0 |
| Total Liabilities | $48.6M | $38.5M | $51.4M |
| Shareholders' Equity | $211.7M | $126.5M | $137.2M |
| Retained Earnings | $-562.7M | $-658.8M | $-783.5M |
| AOCI | $-68.0K | $15.0K | $47.0K |
| Total L&E | $260.3M | $164.9M | $188.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-86.0M | $-96.0M | $-124.7M |
| Non-Cash Adjustments | $-697.0K | $15.0M | $16.9M |
| Working Capital Changes | $-11.3M | $-13.2M | $7.7M |
| Cash from Operations | $-98.0M | $-94.2M | $-100.0M |
| Capital Expenditures | $3.0M | $1.5M | $654.0K |
| Cash from Investing | $59.2M | $9.7M | $-16.1M |
| Cash from Financing | $74.8M | $3.1M | $122.4M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $36.0M | $-81.4M | $6.3M |
| Beginning Cash | $121.2M | $157.2M | $75.8M |
| Ending Cash | $157.2M | $75.8M | $82.2M |
The company operates primarily through its internal research and development pipeline focused on oncology and other therapeutic areas, generating zero revenue from sales as all assets are in pre-commercial stages.
The company is burning cash at a rapid rate of over $100 million annually, leading to a deepening retained earnings deficit that threatens long-term solvency. There is no current revenue stream, making the business entirely dependent on successful clinical trial outcomes or strategic partnerships. The heavy reliance on financing activities for cash flow suggests vulnerability to market conditions affecting investor appetite for late-stage biotech.
Significant cash reserves of over $80 million provide ample runway to advance clinical programs without immediate need for dilutive financing. Substantial investment in R&D ($96.4M) indicates a robust pipeline with potential high-value assets. A strong balance sheet with current assets significantly exceeding current liabilities offers financial stability for long-term development.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.